EUVIMEDEUVIMED entdecken
Crossref

Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors

Wen Shuai, Huan Xiao, Panpan Yang, Yiwen Zhang, Faqian Bu, Yongya Wu, Qiu Sun, Guan Wang iD, Liang Ouyang iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.3c02392 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Wen Shuai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Innovation Center of Nursing Research, Nursing Key Laboratory of Sich…. Hauptthemen laut MEDLINE: Pyrimidines, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: West China Hospital, Sichuan University, China Postdoctoral Science Foundation, Natural Science Foundation of Sichuan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The RAS-RAF-MEK-ERK signaling cascade is abnormally activated in various tumors, playing a crucial role in mediating tumor progression. As the key component at the terminal stage of this cascade, ERK1/2 emerges as a potential antitumor target and offers a promising therapeutic strategy for tumors harboring BRAF or RAS mutations. Here, we identified 36c with a (thiophen-3-yl)aminopyrimidine scaffold as a potent ERK1/2 inhibitor through structure-guided optimization for hit 18. In preclinical studies, 36c showed powerful ERK1/2 inhibitory activities (ERK1/2 IC50 = 0.11/0.08 nM) and potent antitumor efficacy both in vitro and in vivo against triple-negative breast cancer and colorectal cancer models harboring BRAF and RAS mutations. 36c could directly inhibit ERK1/2, significantly block the phosphorylation expression of their downstream substrates p90RSK and c-Myc, and induce cell apoptosis and incomplete autophagy-related cell death. Taken together, this work provides a promising ERK1/2 lead compound for multiple tumor-treatment drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesProtein Kinase InhibitorsAntineoplastic AgentsHumansAnimalsStructure-Activity RelationshipMiceMitogen-Activated Protein Kinase 1ThiophenesMitogen-Activated Protein Kinase 3Cell Line, TumorDrug DiscoveryApoptosisFemaleMice, NudeDrug Screening Assays, AntitumorMolecular StructureCell ProliferationXenograft Model Antitumor AssaysMice, Inbred BALB C

Substanzen

PyrimidinesProtein Kinase InhibitorsAntineoplastic AgentsMitogen-Activated Protein Kinase 1ThiophenesMitogen-Activated Protein Kinase 3

Autor:innen und Institutionen

  • Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, West China Hospital, Sichuan University/West China Schoo…
  • Frontiers Medical Center, Tianfu Jincheng Laboratory, Chengdu 610212, Sichuan, China.

ORCID-Profile: Guan Wang, Liang Ouyang

Förderung

  • West China Hospital, Sichuan University
  • China Postdoctoral Science Foundation
  • Natural Science Foundation of Sichuan Province
  • National Natural Science Foundation of China

Zitieren

APA

Shuai, W., Xiao, H., Yang, P., Zhang, Y., Bu, F., Wu, Y., Sun, Q., Wang, G., & Ouyang, L. (2024). Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c02392

Vancouver

Shuai W, Xiao H, Yang P, Zhang Y, Bu F, Wu Y, et al. Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c02392

BibTeX
@article{Shuai2024,
  author = {Shuai, Wen and Xiao, Huan and Yang, Panpan and Zhang, Yiwen and Bu, Faqian and Wu, Yongya and Sun, Qiu and Wang, Guan and Ouyang, Liang},
  title = {Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.3c02392}
}
Kostenlos starten →